SUSTAINABLE DEVELOPMENT
Innovate. Sustain. Transform.
Save up to 30% on top Physical Sciences & Engineering titles!
Clinical Landscape in Cancer Research
- 1st Edition - March 21, 2025
- Editors: Ranjita Shegokar, Yashwant Pathak
- Language: English
- Paperback ISBN:9 7 8 - 0 - 4 4 3 - 3 0 2 1 9 - 0
- eBook ISBN:9 7 8 - 0 - 4 4 3 - 3 0 2 2 0 - 6
Cancer, a multifaceted disease, remains the leading cause of death worldwide. Ongoing research and technological advancements are continually improving the human understanding of… Read more
Purchase options
Institutional subscription on ScienceDirect
Request a sales quoteCancer, a multifaceted disease, remains the leading cause of death worldwide. Ongoing research and technological advancements are continually improving the human understanding of newer treatment options. This book series aims to provide wide-ranging insights into the current landscape of cancer research, highlighting the recent advancements, current challenges, and future directions.
Cancer varies widely in its formation, microenvironment, location in the body, associated risk factors, detection methodology, and treatment approaches. Early detection and prevention through lifestyle changes, regular screenings, and the awareness of symptoms are crucial for improving outcomes and survival rates. In this book series, the main focus is on trending topics, like new drug delivery, diagnostics, biomarkers, and preclinical and clinical developments in cancer research. Nanotechnology has emerged as a transformative approach in medicine, particularly in the areas of targeted drug delivery systems, imaging, and diagnostics to enhance the therapeutic efficacy and minimize adverse effects in cancer therapy. Advances in pharma, medical device, and diagnostic research, including the development of Trojan-horse therapies and precision treatments/assay kits, continue to enhance the effectiveness of cancer care over the past few decades.
A total of five books are covered in this series:
By integrating basic, applied, and innovative science concepts, this book series fosters a deeper understanding of the disease and paves the way for the development of more effective strategies.
This book series serves as a valuable resource for students, researchers, regulators, and clinicians interested in understanding the complexities of cancer and the innovative approaches researched to combat this deadly disease. Nonetheless, continuous interdisciplinary, cross-country collaborations and cross-science innovation strategies are essential to further reduce the global cancer burden.
Cancer varies widely in its formation, microenvironment, location in the body, associated risk factors, detection methodology, and treatment approaches. Early detection and prevention through lifestyle changes, regular screenings, and the awareness of symptoms are crucial for improving outcomes and survival rates. In this book series, the main focus is on trending topics, like new drug delivery, diagnostics, biomarkers, and preclinical and clinical developments in cancer research. Nanotechnology has emerged as a transformative approach in medicine, particularly in the areas of targeted drug delivery systems, imaging, and diagnostics to enhance the therapeutic efficacy and minimize adverse effects in cancer therapy. Advances in pharma, medical device, and diagnostic research, including the development of Trojan-horse therapies and precision treatments/assay kits, continue to enhance the effectiveness of cancer care over the past few decades.
A total of five books are covered in this series:
- Drug Delivery Landscape in Cancer Research (Vol. 1)
- Biomarker Landscape in Cancer Research (Vol. 2)
- Diagnostic Landscape in Cancer Research (Vol. 3)
- Preclinical Landscape in Cancer Research (Vol. 4)
- Clinical Landscape in Cancer Research (Vol. 5)
By integrating basic, applied, and innovative science concepts, this book series fosters a deeper understanding of the disease and paves the way for the development of more effective strategies.
This book series serves as a valuable resource for students, researchers, regulators, and clinicians interested in understanding the complexities of cancer and the innovative approaches researched to combat this deadly disease. Nonetheless, continuous interdisciplinary, cross-country collaborations and cross-science innovation strategies are essential to further reduce the global cancer burden.
- Contains current studies of the clinical research of different cancer types
- Provides essential information on the most recent developments in clinical cancer research
- Explains current technology and its applications of clinical cancer research
- Holds contributions from oncologists, biomedical engineers, pharmaceutical scientists, and manufacturers
Researchers working across the biosciences in fields of oncology, pharmacology
- Title of Book
- Cover image
- Title page
- Table of Contents
- Copyright
- Contributors
- About the editors
- Preface
- Drug Delivery Systems Landscape in Cancer Research (Vol. 1)
- Biomarker Landscape in Cancer Research (Vol. 2)
- Diagnostics Landscape in Cancer Research (Vol. 3)
- Preclinical Landscape in Cancer Research (Vol. 4)
- Clinical Landscape in Cancer Research (Vol. 5)
- 1. Pancreatic cancer: Advances in clinical research
- Introduction
- Pathophysiology of pancreatic carcinoma
- Indications and manifestations
- Type
- Epidemiology of pancreatic carcinoma
- Genetic processes pancreatic carcinoma
- Pain mechanisms of pancreatic carcinoma
- Worlds statistics
- Genetic mutations
- Dysregulated signaling pathways
- Tumor microenvironment
- Metabolic reprogramming
- Epigenetic alterations
- Tumor heterogeneity
- Immune evasion mechanisms
- Challenges and considerations
- Types of biopharmaceuticals
- Clinical trial phases
- Targeted mechanisms and approaches
- Clinical trial design and considerations
- Challenges and envisage
- Types of regenerative therapies
- Clinical trial phases and design
- Challenges and considerations
- Future directions
- Conclusion
- 2. Spleen cancer: Advances in clinical research
- Introduction
- Factors involved in spleen cancer
- Cellular mechanism
- Clinical trial landscape
- Generic drugs-clinical trials (Table 2.1)
- Zanubrutinib in Japanese participants with B-cell malignancies (NCT04172246)
- A study to investigate the efficacy and safety of bendamustine compared with bendamustine+obinutuzumab (GA101) in participants with rituximab-refractory, indolent nonHodgkin's lymphoma (GADOLIN) - NCT01059630
- Obinutuzumab and ibrutinib as front-line therapy in treating patients with indolent nonHodgkin's lymphomas- NCT03198026
- Study of acalabrutinib and tafasitamab in MZL patients- NCT04646395
- Efficacy and safety study of idelalisib in participants with indolent B-cell nonHodgkin’s lymphomas (DELTA)- NCT01282424
- Carfilzomib with or without rituximab in the treatment of Waldenstrom macroglobulinemia or marginal zone lymphoma—NCT03269552
- UCN-01 and fludarabine in treating patients with recurrent or refractory lymphoma or leukemia—NCT00019838
- Phase II trial of LMB-2, fludarabine and cyclophosphamide for adult T-cell leukemia—NCT00924170
- Doxorubicin hydrochloride, cyclophosphamide, and paclitaxel with or without bevacizumab in treating patients with lymph node-positive or high-risk, lymph node-negative breast cancer—NCT00433511
- Comparison between rituximab plus Zanubrutinib versus rituximab monotherapy in untreated SMZL patients (RITZ)- NCT05735834
- Phase II study of SAR302503 in patients with myelofibrosis- NCT01420770
- An efficacy and safety study of fedratinib compared to best available therapy in subjects with DIPSS-intermediate or high-risk primary myelofibrosis, post-polycythemia vera myelofibrosis, or post-essential thrombocythemia myelofibrosis and previously treated with ruxolitinib (FREEDOM2) -NCT03952039
- Study with SAR302503 in patients with polycythemia vera or essential thrombocythemia—NCT01420783
- Study to evaluate the activity of two dose levels of Imetelstat in participants with intermediate-2 or high-risk myelofibrosis previously treated with Janus Kinase inhibitor- NCT02426086
- A study to evaluate the efficacy of venetoclax monotherapy in relapsed/refractory participants with chronic lymphocytic leukemia (VENICE I)- NCT02756611
- A study of ibrutinib in combination with bendamustine and rituximab in patients with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma –NCT01611090
- Comparison of the treatments of obinutuzumab+venetoclax versus obinutuzumab+chlorambucil in patients with chronic lymphocytic leukemia- NCT02242942
- Study of effectiveness of Axicabtagene Ciloleucel compared to standard of care therapy in patients with relapsed/refractory diffuse large B cell lymphoma (ZUMA-7)- NCT03391466
- Efficacy and safety study of lenalidomide plus R–CHOP chemotherapy versus placebo plus R–CHOP chemotherapy in untreated ABC type diffuse large B-cell lymphoma (ROBUST)- NCT02285062
- Biopharmaceutical clinical trials (Table 2.2)
- A study of selinexor monotherapy in subjects with Janus Kinase inhibitor naïve myelofibrosis and moderate thrombocytopenia (SENTRY-2)- NCT05980806
- Vaccine therapy for treating patients with previously untreated chronic lymphocytic leukemia- NCT01976520
- A study of VAC85135, a Neoantigen Vaccine Regimen, concurrently administered with Ipilimumab for the treatment of myeloproliferative neoplasms- NCT05444530
- Vaccine response with NT-I7- NCT04054752
- Vaccine therapy with or without cryosurgery in treating patients with residual, relapsed, or refractory B-cell nonHodgkin lymphoma- NCT01239875
- Feasibility of autologous tumor cell-TLR9 agonist vaccination for metastatic colorectal cancer- NCT00780988
- Monoclonal antibody therapy in treating patients with lymphoma or colon cancer that has not responded to vaccine therapy- NCT00047164
- Vaccine therapy in treating patients who have undergone a donor stem cell transplant and have cytomegalovirus infection that has not responded to therapy - NCT00509691
- Busulfan, melphalan, and thiotepa in treating patients who are undergoing an autologous stem cell transplant for Hodgkin's or nonHodgkin's lymphoma -NCT00238433
- Assessment of Galectin-9 in rheumatoid arthritis and Its correlation with disease activity- NCT05422313
- System biology of spleen deficiency syndrome - NCT02915393
- Safety, tolerability and preliminary efficacy of engineered red blood cell in patients with advanced malignancies (Reboot-101)- NCT05707325
- Study of traditional Chinese medicine syndrome of hepatocellular carcinoma and colorectal cancer based on system science- NCT03189992
- A clinical study using MEDI-551 in adult participants with relapsed or refractory advanced B-cell malignancies- NCT00983619
- Considerate study - splenic stimulation for RA- NCT05003310
- Regenerative therapies (Table 2.3)
- Lithium carbonate in treating patients with acute intestinal graft-versus-host-disease after donor stem cell transplant - NCT00408681
- Pentostatin, cyclophosphamide, and rituximab with or without bevacizumab in treating patients with B-cell chronic lymphocytic leukemia or small lymphocytic lymphoma- NCT00816595
- A trial of Lenvatinib plus pembrolizumab in participants with hepatocellular carcinoma- NCT03006926
- Solar: Efficacy and safety of cobomarsen (MRG-106) versus active comparator in subjects with mycosis fungoides (SOLAR)- NCT03713320
- Historical trials
- Clinical trials on vaccine therapy
- Vaccine therapy in treating patients with previously treated stage II-III HER2-positive breast cancer- NCT01632332
- Autologous vaccine for follicular lymphoma- NCT01022255
- Conclusion
- 3. CNS cancer: Advances in clinical research
- Introduction
- CNS cancer clinical landscape
- Highlights of CNS cancer clinicals
- Drugs
- Procedures and radiation
- Devices
- Biologics
- Molecular
- Conclusion
- 4. Skin cancer: Advances in clinical research
- Introduction
- Types of skin cancer
- Factors affecting skin cancer progression
- UV rays
- Skin color
- Immunogenic morbidity
- Indoor tanning
- Age
- Viral agent
- World statistics for skin cancer
- Oncogenic pathways
- WNT signaling pathway
- G-protein-coupled receptor-responsive skin cancer progression
- MAPK pathway
- Phosphatidylinositol-3-kinase pathway
- Clinical trials
- Generic drugs
- Imatinib mesylate
- Intralesional versus systemic methotrexate
- Vorinostat
- Nintedanib combined with paclitaxel
- Carboplatin and temozolomide
- Pembrolizumab with imatinib mesylate
- Tazarotene
- Diclofenac and difluoromethylornithine
- Sirolimus
- Cemiplimab with SAR444245
- Nivolumaband/orrelatlimab
- Camrelizumab
- Talimogene Laherparepvec
- Taxoprexin (DHA-paclitaxel)
- Azacitidine combined with pembrolizumab
- Vatalanib
- Carboplatin, paclitaxel, bevacizumab, ± everolimus
- Encorafenib, binimetinib, and nivolumab
- Vaccines and biopharmaceutical clinical trials
- Regenerative therapies
- mRNA trials
- Current challenges for skin cancer clinical trials
- Financial problems
- Clinical trial accrual and completion
- Conclusion
- 5. Lung cancer: Advances in clinical research
- Introduction
- Introduction to lung cancer
- Types of lung cancer
- Histological classification of lung cancer
- Factors affecting lung cancer
- Genetic risk factors
- Family history and high-penetrance genes
- Genetic polymorphisms
- Tobacco consumption and smoking
- Chronic inflammation from infections and other medical conditions
- Pollution
- World statistics
- Molecular biology
- Clinical trial landscape
- Generic drugs-clinical trials
- Docetaxel alone versus cisplatin (CDDP)+docetaxel
- Sintilimab±bevacizumab biosimilar IBI305 combined with pemetrexed and cisplatin
- Metronomic oral vinorelbine and triweekly cisplatin
- Anlotinib
- Irinotecan plus cisplatin with or without simvastatin
- Serplulimab
- Camrelizumab plus apatinib
- Ramucirumab plus atezolizumab
- Nivolumab plus ipilimumab
- Tiragolumab plus atezolizumab
- Eftilagimod alpha (soluble LAG-3 protein) and pembrolizumab
- Osimertinib
- Crizotinib
- Lorlatinib versus crizotinib
- Tepotinib
- Vaccines and immunotherapy
- mRNA trials
- Inhalation and systemic chemotherapy
- Inhalation and systemic chemotherapy trials
- Conclusion
- 6. Thorax cancer: Advances in clinical research
- Introduction
- Types of thoracic cancer
- Lung cancer
- Esophageal cancer
- Pleural cancer
- Thymic cancer
- Other thorax cancers
- Risk factors and causes
- Symptoms
- Research and advancements
- World statistics on thorax cancer
- Trends over time
- Survival rates
- Economic impact
- Cellular mechanism of thoracic cancer
- Molecular and genetic alteration
- Cell signaling promoting
- Clinical landscape of thoracic cancer
- Diagnosis+staging
- Treatment options
- Supportive care
- Healthcare systems
- Future of clinical trials
- Clinical trials
- Historical overview of clinical trials
- Conclusion
- 7. Thyroid cancer: Clinical landscape
- Introduction
- Budget spent globally on clinical trials
- Challenges and regulatory requirements of clinical trials
- World statistics
- Cellular mechanism
- MAPK signaling pathway
- PI3K-AKT/mTOR pathway
- RASSF1–MST1–FOXO3 signaling pathway
- Wnt-β catenin alerting path
- Hypoxia-inducible factor 1α alerting path
- Thyroid-stimulating hormone receptor signaling path
- Clinical trial landscape
- New drugs in clinical trials
- Biopharmaceuticals in clinical trials
- Overview of clinical trials
- Patent information/industry-sponsored clinical trials on thyroid cancer
- Conclusion
- 8. Blood cancer: Advances in clinical research
- Introduction
- Leukemia
- Lymphoma
- Non-Hodgkin lymphoma
- Hodgkin lymphoma
- Myeloma
- World statistics
- Leukemia
- Hodgkin and non-Hodgkin lymphoma
- Myeloma
- Cellular mechanism
- Clinical trials
- Generic drugs clinical trials [37]
- Ibrutinib with nivolumab
- Isavuconazonium sulfate
- CPX-351
- Panobinostat
- Bortezomib
- Piperacillin/tazobactam
- Tenalisib
- Clofarabine
- Ixazomib
- Ribavirin
- Obatoclax mesylate (GX15-070MS)
- Tezacitabine
- Duvelisib
- Belinostat
- Darbepoetin
- Sapanisertib and paclitaxel
- Omacetaxine mepesuccinate
- Pembrolizumab
- Drotrecogin alfa
- Atezolizumab
- Biopharmaceutical clinical trials
- NU 13H05
- mRNA-4157 and pembrolizumab
- V212
- XmAb14045
- COH04S1
- Regenerative therapies—Clinical trials
- CAR-T cells
- Anti-LAG-3 and anti-PD-1
- IBI322
- Gene HSV TK
- Umbilical cord
- Vaccine (mRNA-1273)
- Peptide vaccine
- Clinical trial complexity—Regulatory requirement for pediatric versus geriatric patients
- Conclusion
- 9. Ovarian cancer: Advances in clinical research
- Introduction
- World statistics and factors affecting
- Cellular mechanism
- Candidates in clinical trial
- Generic drugs clinical trials on ovarian cancer
- Biopharmaceutical clinical trials for ovarian cancer
- Regenerative therapies clinical trials for ovarian cancer
- Conclusion
- 10. Stomach and intestinal cancer: Advances in clinical research
- Introduction
- World statistics
- Cellular mechanism
- Intestinal cancer
- Candidates in clinical trial [32]
- Generic drug clinical trials
- A study of paclitaxel with or without ramucirumab (IMC-1211B) in metastatic gastric adenocarcinoma (RAINBOW)
- A clinical trial to evaluate safety and efficacy of endovascular denervation in treatment of cancer pain
- A phase 3 efficacy, safety, and tolerability study of zolbetuximab (experimental drug) plus mFOLFOX6 chemotherapy compared with placebo plus mFOLFOX6 as treatment for gastric and gastroesophageal junction cancer (spotlight)
- Neoadjuvant systemic and peritoneal chemotherapy for advanced gastric cancer (SPECTRA)
- LOGiC—lapatinib optimization study in ErbB2 (HER2)-positive gastric cancer: A phase III global, blinded study designed to evaluated clinical endpoints and safety of chemotherapy plus lapatinib
- A study to assess the antitumor activity, safety, pharmacokinetics, and biomarkers of zolbetuximab (IMAB362) in participants with claudin 18.2 positive, metastatic or advanced unresectable gastric and gastroesophageal junction adenocarcinoma and locoregional gastric or GEJ adenocarcinoma (ILUSTRO)
- A study of zolbetuximab (IMAB362) plus CAPOX compared with placebo plus CAPOX as first-line treatment of subjects with claudin 18.2-positive, HER2-negative, locally advanced unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma (GLOW)
- ASKB589 in combination with CAPOX and PD-1 inhibitor in patients with advanced or metastatic GC/GEJ Adenocarcinoma
- Small intestine cancer
- Biopharmaceutical clinical trials
- Clinical trial of chemotherapy combination cisplatin–fluorouracil–afatinib in patients with inoperable gastric cancer (A-GAPP)
- Safety and immune response to a multicomponent immune-based therapy (MKC1106-PP) for patients with advanced cancer
- Efficacy and safety of sunitinib in metastatic gastric cancer
- A phase I/II study of regorafenib plus avelumab in solid tumors (REGOMUNE)
- At-home cancer-directed therapy versus in clinic for the treatment of patients with advanced cancer
- Vaccine therapy in treating patients with Epstein–Barr virus–related cancer
- TAEK-VAC-HerBy vaccine for brachyury and HER2-expressing cancer
- Overall survival of inoperable gastric/gastroesophageal cancer subjects on treating with LMWH+chemotherapy (CT) versus standard CT (GASTRANOX)
- A study of total neoadjuvant chemotherapy with FLOT VS standard perioperative FLOT in patients with gastric or GEJ cancer (TOGAR)
- Testing the addition of an anticancer drug BAY 1895344, to the usual chemotherapy with FOLFIRI in advanced or metastatic cancers of the stomach and intestines
- Aldesleukin with nivolumab and standard chemotherapy for treatment of gastric cancer with peritoneal metastasis
- M108 plus CAPOX versus placebo plus CAPOX as first-line treatment for plus CAPOX versus placebo plus CAPOX as first-line treatment for claudin 18.2-positive, HER2-Negative, PD L1 CPS<5, locally advanced unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma
- Adding nivolumab to usual treatment for people with advanced stomach or esophageal cancer, PARAMUNE trial
- Testing immunotherapy (atezolizumab) with or without chemotherapy in locoregional MSI-H/dMMR gastric and gastroesophageal junction cancer
- Small intestine cancer
- Combination chemotherapy with or without biological therapy in treating patients with refractory solid tumor or lymphoma
- Testing the anticancer drug, rogaratinib (BAY 1163877), for treatment of advanced sarcoma with alteration in fibroblast growth factor receptors (FGFR 1–4), and in patients with SDH-deficient gastrointestinal stromal tumor
- Fusion protein cytokine therapy after rituximab in treating patients with B cell non-Hodgkin's lymphoma
- Bevacizumab and cediranib maleate in treating patients with metastatic or unresectable solid tumor, lymphoma, intracranial glioblastoma, gliosarcoma, or anaplastic astrocytoma
- Lenalidomide after donor bone marrow transplant in treating patients with high-risk hematologic cancers
- Lenalidomide and combination chemotherapy (DA-EPOCH-R) inn treating patients with MYC-associated B cell lymphomas
- Regenerative therapies—Clinical trials
- Lithium carbonate in treating patients with acute intestinal graft-versus-host-disease after donor stem cell transplant
- Conclusion
- 11. Oral cancer: Clinical landscape
- Introduction
- World statistics
- Cellular mechanisms
- Therapeutics
- Conclusion
- 12. Ocular cancer: Advances in clinical research
- Introduction
- World statistics
- Cellular mechanisms
- Clinical landscape
- Classification of trials based on different drugs
- Drug—13-cis retinoic acid
- Drug—Interferon alfa-2b (IFN)
- Drug—Ipilimumab
- Drug—Selumetinib
- Drug—Iodine 125
- Generic drug clinical trial
- Drug—Olaparib
- Disease—Melanoma
- Drug—Irisin
- Disease—Metastatic malignant melanoma
- Drug—PD-1 (Programmed cell death protein 1) inhibitor
- Biopharmaceutical clinical trials
- Drug—Tiopronin
- Disease—Metastaic choroidal melanoma
- Regenerative therapies
- Drug—Talimogene laherparepvec
- Disease—Uveal melanoma
- Tissue engineering
- Clinical trials of vaccines
- Drug—Talimogene laherparepvec
- Disease—Retinoblastoma
- Drug—Atezolizumabandipilimumab
- Disease—Uveal melanoma
- Conclusion
- Index
- No. of pages: 342
- Language: English
- Edition: 1
- Published: March 21, 2025
- Imprint: Academic Press
- Paperback ISBN: 9780443302190
- eBook ISBN: 9780443302206
RS
Ranjita Shegokar
Ranjita Shegokar holds a Ph.D. degree in Pharmaceutical Technology from the SNDT University, India, and has been a postdoctoral researcher in the Department of Pharmaceutics, Biopharmaceutics and NutriCosmetics at the Free University of Berlin, Germany. Currently, she serves as Chief Scientific Officer (CSO) at Capnopharm GmbH, Germany. She has authored several research articles, book chapters, and presented her research in many national/international conferences. She has filed multiple patent applications in the area of drug delivery and targeting. Besides that, she has edited many trending books in the area of pharmaceutical nanotechnology and drug delivery aspects. For her research, she has received many prestigious national and international awards among them include recently received prestigious German Innovation Award 2022. Her areas of interest include polymeric nanoparticles, nanocrystals, lipid nanoparticles (SLNs/NLCs), nanoemulsions, cancer drug targeting and the role of excipients in delivery systems. (www.ranjitas.com)
Affiliations and expertise
Postdoctoral Researcher, Department of Pharmaceutics, Biopharmaceutics and NutriCosmetics, Free University of Berlin, GermanyYP
Yashwant Pathak
Yashwant Pathak is a Professor and Associate Dean for faculty affairs at the Taneja College of Pharmacy at the University of South Florida, Tampa, USA. Prof. Pathak is also an Adjunct Professor at the Faculty of Pharmacy, Airlangga University, Surabaya, Indonesia. His area of research is in health care education, nanotechnology, drug delivery systems, and nutraceuticals.
Affiliations and expertise
Professor and Associate Dean, Faculty Affairs, College of Pharmacy, University of South Florida, Tampa, USARead Clinical Landscape in Cancer Research on ScienceDirect